OCS (47) PHAT (34) INDP (44) DMAC (44) ⌘ Pro Terminal →

Aquestive Therapeutics Inc. (AQST) — RQD Stock Rating Cockpit

$3.89 -3.71% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.86

Aquestive Therapeutics Inc. (AQST) carries a Roarable Rating of E (Strong Sell) with 18/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (18/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $507.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AQST Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AQST stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Aquestive Therapeutics Inc. (NASDAQ: AQST) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 18/100 at a spot price of $3.89 (-3.71% 1D, market cap $507.1M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AQST ranks #1005 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AQST compare to OCS and PHAT in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AQST carries a Roarable E (18/100 RQD), trailing P/E of N/A, gross margin of 58.3%, and ROIC of -35.0%. By comparison, OCS (Oculis Holding AG) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $507.5M) and PHAT (Phathom Pharmaceuticals Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $503.2M). Among the 5-stock peer group, AQST leads on earnings multiple (N/A) while AQST leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AQST?

▼

Per AQST's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001398733), Aquestive Therapeutics Inc. generated $44.5M in revenue (-22.6% YoY), -$83.8M in net income, and -$53.0M in free cash flow against $160.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.86 (-0.86%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (18/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-18% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AQST)Realized 20D OHLCV Swing Band: ±11.6%

Deterministic 5-Pillar Attribution (18/100 Composite)

🔍 WHY AQST SCORES 18/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+5/20 pts (28% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 58.3% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+4/20 pts (22% of score)

20D Institutional Volume Accumulation (±11.6% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$4.81-20.4% Next Q

Q2 (-2Q)

Grade E$3.83+3.7% Next Q

Q3 (-1Q)

Grade E$3.97-2% Next Q

Current

Grade E$3.89-12.2% Hist 90D α

Trajectory: E (26) → E (18)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AQST Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AQST currently carries a cautious 18/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.65) and Max Pain ($4.08) forces dealer call-delta covering toward $7.21.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AQST• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “AQST Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 18%NO 82%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

42.730 Oversold · 70 Hot

ALTMAN-Z SHIELDDISTRESS RISK (<1.8)

0.20>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

3 / 99-Pt Accounting

52-WEEK LASER RANGE24% OF RANGE

L: $3$3.89H: $7

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 5 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 7 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 6 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on AQST

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (25)

-35.0% ROIC with 58.3% gross margin and -10.45% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (18)

Altman-Z 0.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (18)

7/40 institutional & smart-money positioning score with 4/20 macro alignment.

Bull Case: Why Buyers Like AQST

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AQST)

✓Walkthrough of AQST's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AQST // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -7.82%▲ ASCENDING CHANNEL

2026-11-02O $4.23H $4.23L $3.89C $3.89VOL 2.02M

RES: $5.73SUP: $3.67SMA50: $4.65SMA200: $4.21

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AQST Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AQST Butterfly Map → + Track AQST →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -22.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AQST today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AQST. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AQST today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AQST)

Health Care Rank #1005 of 1016 ⚔️ OCS vs AQST Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AQST vs. OCS, PHAT, INDP, DMAC)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Aquestive Therapeutics Inc. (AQST) ranks #1005 by composite RQD confidence (18/100, grade E) and #449 by equity capitalization ($507.1M). Within this direct 5-issuer industry benchmark cohort, AQST leads on earnings valuation at N/A trailing P/E, while AQST leads on capital efficiency and profitability with -35.0% ROIC and 58.3% gross margin. OCS currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with AQST at 18/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AQST ACTIVE Aquestive Therapeutics Inc.	E	18/100	—	58.3%	-35.0%	-3.71%	$507.1M	Benchmark Subject
OCS Oculis Holding AG	D	47/100	—	—	—	+0.24%	$507.5M	/ocs-vs-aqst →
PHAT Phathom Pharmaceuticals Inc.	E	34/100	—	87.1%	-35.0%	-7.72%	$503.2M	/phat-vs-aqst →
INDP Indaptus Therapeutics Inc.	D	44/100	—	—	-35.0%	-7.48%	$513.0M	/indp-vs-aqst →
DMAC DiaMedica Therapeutics Inc.	D	44/100	—	—	-35.0%	-2.84%	$513.4M	/dmac-vs-aqst →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001398733

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aquestive Therapeutics Inc. (AQST) reported GAAP revenue of $44.5M (-22.6% vs. FY2024 revenue of $57.6M , and -11.9% cumulative change since FY2023) , GAAP net income of -$83.8M, operating cash flow of -$52.4M, and free cash flow of -$53.0M (-47.5% YoY). On the balance sheet, AQST closed FY2025 with $160.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$44.5M	-$83.8M	-$52.4M	-$53.0M	$160.4M	—
FY2024 (FY)	2024-12-31	$57.6M	-$44.1M	-$35.8M	-$35.9M	$101.4M	—
FY2023 (FY)	2023-12-31	$50.6M	-$7.9M	-$6.4M	-$6.4M	—	—

3. AQST Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AQST stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does AQST compare to OCS and PHAT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for AQST?

Where is AQST trading relative to its 50-day, 200-day, and 52-week technical levels?

AQST last traded at $3.89 (-3.71% on volume of 2,420,007 shares), positioning the stock -16.34% below its 50-day simple moving average ($4.65) and -7.60% below its 200-day simple moving average ($4.21). Across its 52-week range of $2.93 to $6.87, AQST sits at the 24.4% percentile with a 14-day RSI of 42.7 (NEUTRAL RANGE) and an implied next-earnings move of ±11.6% ($3.44 to $4.34).

AQST Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell AQST stock right now?

Aquestive Therapeutics Inc. (AQST) currently earns a Roarable Rating of E (Strong Sell — SELL) with 18/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is AQST's 12-month price target and RQD AI Jury consensus?

AQST's 12-month base price target is $3.19 (range $2.49 to $7.21), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: AQST RQD Cockpit AQST 12M Forecast AQST Earnings & Move AQST Dividends & DRIP AQST Insiders & 13F AQST Whale Options AQST Profit Sankey AQST News & Why

ROARABLE RATING BRIEF • RQD 18/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

AQST — Aquestive Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:35:43Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, AQST scores 18 out of 100 and receives a letter grade of E, with the verdict "Roarable Strong Sell — Forensic Risk / Avoid." Each pillar is scored out of 20:

Fundamental Cash Engine: 5 / 20. Per the RQD rating, ROIC is -35% and FCF yield is -10.45%. For an investor, this means the business is currently consuming capital rather than generating it, so any valuation case has to rest on future cash flows that the reported figures do not yet show.
Whale 13F Flow: 4 / 20. The RQD rating cites institutional accumulation and options positioning as weak. The holders section contains no 13F detail, so the specific ownership trend behind this score cannot be verified from the source data.
Insider Conviction: 3 / 20. Per the RQD rating, SEC Form 4 and Congressional PTR cluster flow is scored low. Investors typically read weak insider conviction as a lack of internal confidence signal; the individual transactions are not itemized in the source data.
Macro Regime Fit: 4 / 20. Per the RQD rating, beta is 1.0 and sector sensitivity is scored weak. An investor should note that the stock moves roughly in line with the market, so this score reflects limited defensive or regime-driven upside rather than extra volatility.
Forensic Balance Sheet: 2 / 20. Per the RQD rating, Altman Z is 0.2, Piotroski F is 3/9, and Debt/Equity is 0.5. The Altman Z reading sits in a distress-type range and the Piotroski score is weak, which is the single largest drag on the overall rating and the main reason the verdict is avoid-oriented.

Taken together, the rating points to a company with negative operating economics, a strained balance-sheet signal, and weak ownership and insider signals. The upside case an investor would need to underwrite is a return to cash generation, which the reported financials have not yet demonstrated. Valuation tradeoffs are difficult to assess because the P/E and EV/EBITDA measures are not available in the source data, so the rating's forensic and cash-flow pillars carry most of the analytical weight.

Business

Aquestive Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company has a market capitalization of $0.5B. The source data does not detail its specific products, customers, or revenue model, so how the company makes money cannot be described beyond its reported revenue figures in the Financial Trend section.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$44.5M	$-71.1M	$-83.8M	N/A	$-53.0M	$121.2M	N/A
FY 2024	$57.6M	$-30.8M	$-44.1M	N/A	$-35.9M	$71.5M	N/A
FY 2023	$50.6M	$-15.1M	$-7.9M	N/A	$-6.4M	N/A	N/A

Per the SEC financials, revenue fell from $57.6M in FY 2024 to $44.5M in FY 2025, while net losses widened from $-44.1M to $-83.8M. Per the market data, the gross margin is 58.3%, but the operating and net margins are both -60%, and ROIC is -35%. The Altman Z-Score of 0.2 and Piotroski F-Score of 3/9 (per the Roarable RQD rating) indicate a weak financial position, and Debt/Equity is 0.5. Reported cash of $121.2M in FY 2025 is above the FY 2024 level of $71.5M, though the FCF figures remain negative in every reported year.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the most prominent items are:

Risk Watch (RED): A Schubert Jonckheer & Kolbe report references a possible false-statements investigation following a 37% stock drop, flagged as a risk item.
Catalyst (GREEN): A Seeking Alpha report references FDA acceptance of an Anaphylm resubmission, flagged as a positive catalyst.
Market Wire (YELLOW): Yahoo Finance, ChartMill, StockInvest.us, and TradingView items reference Q3 2026 earnings, a GF Value downside estimate of 25%, and general market positioning.

The Butterfly supply-chain graph reports no supply-chain links and no proprietary signals, so no butterfly-derived signal is available.

Open Questions

What is the scope and status of the possible false-statements investigation referenced in the news feed, and does it carry financial exposure?
What drives the widening FY 2025 net loss to $-83.8M, and what is the expected path to positive FCF?
What are the current debt obligations, given that the debt field is N/A for every period?
What is the commercial outlook for the Anaphylm product implied by the FDA resubmission acceptance?
What are the forward earnings and valuation multiples, which are unavailable in the source data?

AQST Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Aquestive Therapeutics Inc. (AQST) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AQST Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 4h ago

Earnings To Watch: Aquestive Therapeutics Inc (AQST) Q3 2026 -- GF Value Sees 25% Downside

Yahoo Finance report covering Aquestive Therapeutics Inc. (AQST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ChartMill • 7h ago

AQST News | AQUESTIVE THERAPEUTICS INC (NASDAQ:AQST)

ChartMill report covering Aquestive Therapeutics Inc. (AQST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StockInvest.us • 10h ago

Aquestive Therapeutics Stock Price Forecast. Should You Buy AQST?

StockInvest.us report covering Aquestive Therapeutics Inc. (AQST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Schubert Jonckheer & Kolbe • 13h ago

Aquestive Therapeutics, Inc. (AQST) Investor Alert: Possible False Statements After 37% Stock Drop

Schubert Jonckheer & Kolbe report covering Aquestive Therapeutics Inc. (AQST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Seeking Alpha • 16h ago

Aquestive: FDA Acceptance Of Anaphylm Resubmission Makes For Rating Upgrade (NASDAQ:AQST)

Seeking Alpha report covering Aquestive Therapeutics Inc. (AQST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 19h ago

Aquestive Therapeutics, Inc. Estimates – NASDAQ:AQST

TradingView report covering Aquestive Therapeutics Inc. (AQST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Richard J. Daly reports no directly held common shares in Aquestive Therapeutics (AQST).

Stock Titan report covering Aquestive Therapeutics Inc. (AQST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 6d ago

Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET

WARREN, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' liv

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AQST Bull vs. Bear Conversation Board — What's Your Call at $3.89?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AQST 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $3.56 (-11.9%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is AQST (E • RQD 18/100) a Buy at $4.04?

Welcome to the AQST (Aquestive Therapeutics Inc.) Roar Pit. Current RQD Composite is 18/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $3.31 (-18.1%)

Spot @ $4.04

Pump the brakes on AQST — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on AQST, but look at what you are paying: current EV/EBITDA multiples with 58.3% gross margins. Unless Aquestive Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $4.89 (+21.0%)

Spot @ $4.04

AQST cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on AQST, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $4.04 (52-wk range $2.93 - $6.87), any beat on forward guidance forces shorts and underweight funds to chase.